Tumor size is not everything: Advancing radiomics as a precision medicine biomarker in oncology drug development and clinical care. A report of a multidisciplinary workshop coordinated by the RECIST Working Group Journal Article

  

Authors:	Nakajima, E. C.; Simpson, A.; Bogaerts, J.; de Vries, E. G. E.; Do, R.; Garralda, E.; Goldmacher, G.; Kinahan, P. E.; Lambin, P.; LeStage, B.; Li, Q.; Lin, F.; Litière, S.; Perez-Lopez, R.; Petrick, N.; Schwartz, L.; Seymour, L.; Shankar, L.; Laurie, S. A.
Article Title:	Tumor size is not everything: Advancing radiomics as a precision medicine biomarker in oncology drug development and clinical care. A report of a multidisciplinary workshop coordinated by the RECIST Working Group
Abstract:	Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials. This paper by the RECIST Working Group outlines a path to realize the potential of radiomics as a precision biomarker.
Keywords:	guidelines; inhibitors; bone metastases; trials; images; response evaluation criteria; cancer
Journal Title:	JCO Precision Oncology
Volume:	8
ISSN:	2473-4284
Publisher:	American Society of Clinical Oncology
Date Published:	2024-09-01
Start Page:	e2300687
Language:	English
ACCESSION:	WOS:001283738000015
DOI:	10.1200/po.23.00687
PROVIDER:	wos
PUBMED:	38635935
Notes:	Article -- Erratum issued, see DOI: 10.1200/PO.24.00309 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/218431